04 Pharmacotherapy Vol 1 Neurology
04 Pharmacotherapy Vol 1 Neurology
04 Pharmacotherapy Vol 1 Neurology
Neurology
Timothy E. Welty, Pharm.D., FCCP, BCPS
Drake University
Des Moines, Iowa
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-83
Neurology
Self-Assessment Questions
Questions 4 and 5 pertain to the following case.
Answers and explanations to these questions may be
R.H. is a 62-year-old man who presents to the ED for
found at the end of this chapter.
new-onset right-sided weakness and slurred speech
that began 6 hours ago. He has a history of hyperten-
1. T.L. is a 35-year-old man with complex partial sei-
sion and coronary artery disease. His medication list
zures who is otherwise healthy. He was initiated on
includes atenolol 50 mg/day orally, hydrochlorothi-
phenytoin after a seizure about 2 months ago. He
azide 25 mg/day orally, and aspirin 81 mg/day orally.
currently takes phenytoin 100 mg 3 capsules orally
His vital signs include blood pressure 160/92 mm Hg,
every night. During his clinic visit, he continues
heart rate 92 beats/minute, respiratory rate 14 breaths/
to have seizures, and he has no signs of toxicity.
minute, weight 85 Kg, and temperature 38°C. The ED
He is allergic to sulfa drugs. His phenytoin serum
physician asks for your opinion on treatment options.
concentration is 11.2 mcg/mL. Which is the best
new phenytoin dose for this patient?
4. Which reply is best, given this information?
A. 260 mg/day.
A. R.H. should be treated with alteplase 7.65 mg
B. 300 mg/day. over 1 minute followed by 68.85 mg over 60
C. 350 mg/day. minutes.
D. 400 mg/day. B. R.H. should be treated with aspirin 81 mg/day
C. R.H. should be treated with clopidogrel 300
2. B.V. is a 28-year-old woman brought to your emer- mg loading dose, followed by 75 mg/day with
gency department (ED) for treatment of status aspirin 81 mg/day for 90 days.
epilepticus. She receives lorazepam 4 mg intrave-
D. R.H. should be treated with aspirin 25 mg/
nously with subsequent seizure cessation. Which
dipyridamole 200 mg extended release for 30
medication is the best next treatment step for B.V.?
days.
A. Topiramate.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-84
Neurology
5. R.H. is treated appropriately and survives his stroke. 8. W.S. is a 57-year-old man initiated on rasagiline
As part of his discharge treatment plan from rehabil- for treatment of his newly diagnosed Parkinson
itation 3 months later, you evaluate his risk factors disease. He develops a cough, body aches, and
for a second stroke. Which medication for second- nasal congestion. Which medication is best to treat
ary stroke prevention is best to initiate at this time? W.S.’s symptoms?
A. Dipyridamole. A. Guaifenesin.
B. Aspirin. B. Dextromethorphan.
C. Warfarin. C. Tramadol.
D. Clopidogrel. D. Pseudoephedrine.
Questions 6 and 7 pertain to the following case. Questions 9 and 10 pertain to the following case.
C.P. is a 69-year-old man given a diagnosis of Parkinson R.M. is a 47-year-old woman with long-standing
disease 7 years ago. He states that he is most bothered migraine headaches. Her headache pain is easily
by his bradykinesia symptoms. On examination, he relieved with sumatriptan 100 mg orally as needed.
also has a pronounced tremor, postural instability, and However, with her last dose she had substernal chest
masked facial expression. He currently takes carbidopa/ pain radiating to her left arm. She reported to her local
levodopa/entacapone 25 mg/100 mg/200 mg orally four ED, where she had a complete workup. Her final diag-
times daily, ropinirole 1 mg orally three times daily, and noses were coronary artery disease and hypertension.
selegiline 5 mg orally twice daily. He has no drug aller- For these conditions, she was initiated on hydrochloro-
gies. He also describes a worsening of his Parkinson thiazide 25 mg orally every morning.
disease symptoms, which fluctuate randomly during
the day. He has developed a charting system for his 9. Which drug is best for R.M. to use for her migraine
symptoms during the day, and no relationship seems to headaches?
exist with the time he is scheduled to take his carbi- A. Frovatriptan.
dopa/levodopa/entacapone doses.
B. Zolmitriptan.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-85
Neurology
11. W hich drug therapy is best for L.M.’s multiple 15. Which treatment is best is best for B.T.’s symptoms?
sclerosis? A. Phenytoin 200 mg at bedtime.
A. Cyclophosphamide. B. Lidocaine 5% patch applied to soles of feet at
B. Methylprednisolone. bedtime and removed in the morning.
C. Azathioprine. C. Tramadol 50 mg three times daily.
D. Fingolimod. D. Valproate 250 mg two times daily.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-86
Neurology
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-87
Neurology
I. EPILEPSY
A. Epidemiology
1. 10% of the population will have a seizure.
2. About 50 million people worldwide have epilepsy.
3. About 50% of patients with a new diagnosis become seizure free on their first treatment, with up to 70%
becoming seizure free after treatment adjustment.
B. Classification of Seizures: Seizures are currently classified according to the International League Against
Epilepsy (ILAE) scheme, adopted in 1981, with modifications in 2001 and 2010 (Berg AT, Berkovic SF,
Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of
the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51:676-85). There is
a proposal to change the classification of epilepsy according to etiology (Scheffer IE, French, J, Hirsch E,
et al. Classification of the epilepsies: new concepts for discussion and debate—special report of the ILAE
Classification Task Force of the Commission for Classification and Terminology. Epilepsia Open 2016:1-8).
1. Focal seizures are conceptualized as originating at some point within networks limited to one
hemisphere.
a. No specific classification within focal seizures is recommended.
b. The terms simple partial seizure, complex partial seizure, and secondarily generalized seizure
have been eliminated from classification; however, they are still used to describe seizures.
2. Generalized seizures are conceptualized as originating at some point within and rapidly engaging bilat-
erally distributed neural networks.
a. Absence: Typical absence seizures are brief and abrupt, last 10–30 seconds, and occur in clus-
ters. Absence seizures usually result in a short loss of consciousness, or the patient may stare,
be motionless, or have a distant expression on his or her face. Electroencephalograms (EEGs)
performed during seizure activity usually show three Hz spike-and-wave complexes. Absence
seizures can be further classified as typical, atypical, myoclonic absence, and eyelid myoclonia.
b. Myoclonic: Consist of brief, rapid jerking movements of the entire body or the upper and occa-
sionally lower extremities. Myoclonic seizures can be further classified as myoclonic, myoclonic
atonic, or myoclonic tonic.
c. Tonic-clonic: Typically, there are five phases of a primary tonic-clonic seizure: flexion, extension,
tremor, clonic, and postictal. During the flexion phase, the patient’s mouth may be held partly
open, and the patient may have upward eye movement, involvement of the extremities, and loss of
consciousness. In the extension phase, the patient may be noted to extend his or her back and neck;
have contraction of thoracic and abdominal muscles; be apneic; and have flexion, extension, and
adduction of the extremities. The patient may cry out as air is forced from the lungs in this phase.
The tremor phase occurs as the patient goes from tonic rigidity to tremors and then to a clonic state.
During the clonic phase, the patient will have rhythmic jerks. The length of the entire seizure is
usually 1–3 minutes. After the seizure, the patient may be postictal. During this time, the patient
can be difficult to arouse or very somnolent. Before the seizure, a patient may have a prodrome but
not an aura.
d. Clonic: Only the clonic phase of a tonic-clonic seizure; rhythmic, repetitive, jerking muscle
movements
e. Tonic: Only the flexion or extension phases of a tonic-clonic seizure
f. Atonic: Characterized by a loss of muscle tone. Atonic seizures are often described as drop attacks,
in which a patient loses tone and falls to the ground.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-88
Neurology
C. Diagnosis
1. Physical examination should be performed, with special attention to neurologic findings. The neuro-
logic examination may include examination of the head, vision, cranial nerves, motor function, cere-
bellar function, and sensory function.
2. Laboratory tests are based on the history and physical examination results; a full diagnostic onslaught is
unnecessary in many patients. Because metabolic causes of seizures are common, serum glucose, elec-
trolytes, calcium, complete blood cell counts, and renal function tests may be necessary. A toxicology
screen may also be prudent.
3. EEGs are used to help confirm the diagnosis, classify seizures, locate the site of the seizures, and select
the best seizure medication. The best time to perform an EEG is while the patient is having seizures. If
it is not possible to perform the EEG during seizures, it should be performed as soon after the seizure
as possible. Depending on the clinical situation, an EEG may be obtained under normal conditions,
when the patient is sleep deprived, or when the patient is asleep. Patients whose seizures are difficult to
diagnose or control may need prolonged closed-circuit video–EEG monitoring. Keep in mind that an
interictal (when the patient is not having clinical seizures) EEG may be normal, but that this does not
preclude the diagnosis of epilepsy.
4. Magnetic resonance imaging (MRI) is the neuroimaging technique of choice for epilepsy. Computed
tomography (CT) scanning can be useful in finding brain lesions when MRI cannot be performed in a
timely fashion.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-89
Neurology
D. Treatment
1. Medications (see Tables 1–5)
a. Benzodiazepines
i. Mechanism of action: Augment γ-aminobutyric acid–mediated chloride influx
ii. Tolerance may develop: Usually used as adjunctive, short-term therapy
iii. Most commonly used drugs: Chlorazepate (Tranxene), clobazam (Onfi), clonazepam (Klonopin),
diazepam (Valium), and lorazepam (Ativan)
iv. All benzodiazepines are controlled substances, scheduled as C-IV.
v. Nonepileptic indications: Chlorazepate (anxiety disorders, anxiety), clonazepam (panic disor-
der with or without agoraphobia), lorazepam (anxiety disorders, anxiety)
b. Brivaracetam (Briviact)
i. Mechanism of action: Unknown mechanism but has high affinity for synaptic vesicle protein
2A (SV2A)
ii. Adverse effects: Somnolence, sedation, dizziness, fatigue
iii. Drug interactions: Carbamazepine, phenobarbital, phenytoin
c. Carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Teril)
i. Mechanism of action: Fast sodium channel blocker
ii. Pharmacokinetics: Enzyme inducer, autoinduction
iii. Adverse effects: Rash (occurs after a delay of 2–8 weeks), syndrome of inappropriate antidi-
uretic hormone release, aplastic anemia, thrombocytopenia, anemia, leukopenia
iv. Extended-release tablets (Tegretol XR) 100, 200, and 400 mg; extended-release capsules
(Carbatrol) 100, 200, and 300 mg available. Dosing is still twice daily. Do not crush or chew.
Extended-release capsules (Carbatrol) can be opened and sprinkled on food. Ghost tablets can
be seen in the stool with the extended-release tablets (Tegretol XR).
v. Patients with the HLA-B*1502 allele are at a 10-fold elevated risk of Stevens-Johnson syndrome.
(a) Testing is recommended for Asians (including Indians).
(b) More than 15% of populations in Hong Kong, Malaysia, the Philippines, and Thailand
have this allele.
vi. Patients with the HLA-A*3101 allele are also at a 12-fold elevated risk of hypersensitivity
syndrome and a 3-fold elevated risk of maculopapular exanthema.
(a) The prevalence of this allele is 2%–5% in northern European populations and 9.1% of
Japanese populations.
(b) No recommendations for testing for this allele have been issued.
vii. Nonepileptic indication: Trigeminal neuralgia
d. Eslicarbazepine acetate (Aptiom)
i. Mechanism of action: Fast sodium channel blocker
ii. Prodrug for (S)-(+)-licarbazepine, an active metabolite of oxcarbazepine
iii. Adjust dose if creatinine clearance (CrCl) is less than 50 mL/minute/1.73 m 2.
e. Ethosuximide (Zarontin)
i. Mechanism of action: T-type calcium current blocker
ii. Useful only for absence seizures
f. Ezogabine (Potiga) – Will be withdrawn from the market effective June 2017, because of
limited use
i. Mechanism of action: Potassium channel opener
ii. Adverse effects: Urinary retention, hallucinations, QT prolongation, pigment changes in
retina, or blue discoloration of the lips, nail beds, face, legs, sclera, and conjunctiva
iii. Monitoring recommendations: Baseline and periodic eye examinations (every 6 months) with
visual acuity testing and dilated fundus photography
iv. Ezogabine is a schedule V controlled substance
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-90
Neurology
g. Felbamate (Felbatol)
i. Mechanism of action: Blocks glycine site on N-methyl-d-aspartate receptor
ii. Serious adverse effects: Hepatotoxicity, aplastic anemia. Patient or guardian must sign consent
form. Used only when seizures are severe and refractory to other medications and when the
benefit clearly outweighs the potential adverse effects
h. Fosphenytoin (Cerebyx)
i. Mechanism of action: Prodrug for phenytoin; fast sodium channel blocker
ii. Uses: Parenteral formulation for loading or maintenance dosing in place of phenytoin; status
epilepticus
iii. Pharmacokinetics: Enzyme inducer, nonlinear kinetics
iv. Dosing: Phenytoin equivalents are used; 1 mg of phenytoin = 1.5 mg of fosphenytoin = 1 mg
of phenytoin equivalent. Intramuscular or intravenous dosing is appropriate.
v. Adverse effects: Hypotension, perianal itching, other adverse effects of phenytoin
vi. Advantages over phenytoin
(a) Intramuscular or intravenous dosing
(b) Phlebitis is minimized.
(c) Infusion can be up to 150 mg of phenytoin equivalents per minute.
(d) Can deliver in normal saline solution or D5W (5% dextrose [in water] injection)
i. Gabapentin (Neurontin)
i. Mechanism of action: Inhibition of α2δ subunit of voltage-dependent calcium channels
ii. Pharmacokinetics: Not metabolized, eliminated renally; adjustments may be necessary for
renal dysfunction and hemodialysis.
iii. Nonepileptic indication: Postherpetic neuralgia pain
iv. Doses often exceed product information maximum of 3600 mg/day.
v. Extended-release tablets (Gralise) 300 and 600 mg are available. Their indication is for posth-
erpetic neuralgia, not epilepsy.
vi. Gabapentin enacarbil (Horizant) extended-release tablets 300 and 600 mg are available. This
agent is a prodrug for gabapentin and is indicated for postherpetic neuralgia and restless legs
syndrome, not epilepsy.
j. Lacosamide (Vimpat)
i. Mechanism of action: Slow sodium channel blocker
ii. Maximal dose of 300 mg/day with a CrCl of 30 mL/minute/1.73 m 2 or less or with mild to
moderate hepatic impairment
iii. Adverse effects: PR interval prolongation or first-degree atrioventricular block; baseline and
steady-state electrocardiogram recommended in patients with known cardiac conduction
problems, taking medications known to induce PR interval prolongation, or with severe car-
diac disease
iv. Controlled substance schedule V because of euphoric effects
v. Parenteral formulation: Has a U.S. Food and Drug Administration (FDA) indication only for
replacement of oral formulation
k. Lamotrigine (Lamictal)
i. Mechanism of action: Decreases glutamate and aspartate release, delays repetitive firing of
neurons, blocks fast sodium channels
ii. Rash is a primary concern; lamotrigine must be titrated slowly to avoid a rash.
iii. Valproic acid decreases lamotrigine metabolism; this interaction requires even slower titration
and lower final doses.
iv. Estrogen-containing oral contraceptives increase lamotrigine clearance, so twice the amount
of lamotrigine may be necessary.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-91
Neurology
v. Extended-release tablets (Lamictal XR) are available (25 mg, 50 mg, 100 mg, 200 mg, 250 mg,
300 mg).
vi. Nonepileptic indications: Maintenance treatment of bipolar I mood disorder
l. Levetiracetam (Keppra)
i. Mechanism of action: May prevent hypersynchronization of epileptiform burst firing and
propagation of seizure activity
ii. Pharmacokinetics: Not metabolized extensively, adjust dose in renal dysfunction, no drug
interactions with other seizure medications
iii. Parenteral use: Currently indicated by the FDA only for replacement of oral dosing; however,
sometimes used for status epilepticus
iv. Extended-release tablets (500 mg, 750 mg) are available for once-daily dosing.
m. Oxcarbazepine (Trileptal)
i. Mechanism of action: Fast sodium channel blocker
ii. Pharmacokinetics: Active metabolite 10-monohydroxy oxcarbazepine; enzyme inducer, no
autoinduction
iii. Adverse effects: Hyponatremia more common than with carbamazepine (increased dose and
increased age increase risk of hyponatremia); blood dyscrasias less common than with carba-
mazepine; 25%–30% of patients with hypersensitivity to carbamazepine will have hypersen-
sitivity to oxcarbazepine; rash
iv. Extended-release tablets (Oxtellar XR) are available (150 mg, 300 mg, 600 mg).
n. Perampanel (Fycompa)
i. Mechanism of action: Noncompetitive antagonist of the inotropic α-amino-3-hydroxy-
5-methyl-4-isoxazole propionic acid (AMPA) glutamate receptor
ii. Pharmacokinetics: 95%–96% protein bound to albumin and α1-acid glycoprotein; metabolized
by cytochrome P450 (CYP) 3A4 and 3A5; 105-hour half-life
iii. Adverse effects: Neuropsychiatric effects (irritability, aggression, anger, anxiety), dizziness,
gait disturbance, weight gain
iv. Perampanel is a schedule III controlled substance.
o. Phenobarbital (Luminal)
i. Mechanism of action: Increases γ-aminobutyric acid–mediated chloride influx
ii. Pharmacokinetics: Enzyme inducer
iii. Adverse effects: Hyperactivity, cognitive impairment
iv. Phenobarbital is a schedule IV controlled substance
v. Nonepileptic use: Anxiety
p. Phenytoin (Dilantin, Phenytek)
i. Mechanism of action: Fast sodium channel blocker
ii. Pharmacokinetics: Enzyme inducer, nonlinear kinetics
iii. Administration considerations
(a) Intravenous formulation: Very basic product. Phlebitis and extravasation are concerns;
hypotension; maximal infusion rate of 50 mg/minute. Can prepare only in normal saline
solution
(b) Oral suspension: Must be shaken well; adheres to feeding tubes and is bound by enteral
nutrition products
iv. Dose-related adverse effects: Nystagmus, ataxia, drowsiness, cognitive impairment
v. Non–dose-related adverse effects: Gingival hyperplasia, hirsutism, acne, rash, hepatotoxicity,
coarsening of facial features
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-92
Neurology
q. Pregabalin (Lyrica)
i. Mechanism of action: Inhibition of α2δ subunit of voltage-dependent calcium channels
ii. Pharmacokinetics: Not metabolized, renally excreted, reduce dose in renal dysfunction
iii. Adverse effects: Drowsiness, blurred vision, weight gain, edema, angioedema, creatine kinase
elevations (three reports of rhabdomyolysis), rash
iv. Schedule V controlled substance: Insomnia, nausea, headache, diarrhea reported after abrupt
discontinuation
v. Nonepileptic indications: Neuropathic pain associated with diabetic neuropathy, postherpetic
neuralgia, and fibromyalgia
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-93
Neurology
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-94
Neurology
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-95
Neurology
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-96
Neurology
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-97
Neurology
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-98
Neurology
r. Primidone (Mysoline)
i. Mechanism of action: Increases γ-aminobutyric–mediated chloride influx
ii. Metabolized to phenobarbital and phenylethylmalonamide
iii. Primidone, phenobarbital, and phenylethylmalonamide all have antiepileptic action.
iv. Pharmacokinetics: Enzyme inducer
v. Also used for essential tremor
s. Rufinamide (Banzel)
i. Mechanism of action: Fast sodium channel blocker
ii. Pharmacokinetics: Absorption increased by food (should be administered with food); metabo-
lized by hydrolysis rather than through CYP enzymes
iii. Decreases concentrations of ethinyl estradiol and norethindrone
iv. Has an FDA indication only for Lennox-Gastaut syndrome
v. Slightly shortens the QT interval and therefore should not be used in patients with familial
short QT syndrome
vi. Available as an oral solution
t. Tiagabine (Gabitril)
i. Mechanism of action: Blocks γ-aminobutyric reuptake in the presynaptic neuron
ii. Associated with new-onset seizures and status epilepticus in patients without epilepsy
u. Topiramate (Topamax)
i. Mechanism of action: Fast sodium channel blocker, enhances γ-aminobutyric activity, and
antagonizes AMPA/kainate activity, weak carbonic anhydrase inhibitor
ii. Pharmacokinetics: Not extensively metabolized, eliminated in urine
iii. Adverse effects: Drowsiness, paresthesias, psychomotor slowing (titrate slowly), weight loss,
renal stones, acute angle closure glaucoma, metabolic acidosis, and hyperthermia (associated
with decreased perspiration, or oligohidrosis)
iv. Extended-release formulations (Trokendi XR, Qudexy XR)
v. Nonepileptic indication: Prophylaxis of migraine headaches
v. Valproic acid (Depacon, Depakene, Depakote, Stavzor)
i. Mechanism of action: Blocks T-type calcium currents, blocks sodium channels, increases
γ-aminobutyric production
ii. Pharmacokinetics: Enzyme inhibitor
iii. Parenteral use: Has FDA indication only for replacement of oral dosing; however, sometimes
used for status epilepticus, especially if absence status epilepticus
iv. Adverse effects: Hepatotoxicity, nausea and vomiting, weight gain, interference with platelet
aggregation, pancreatitis, alopecia, tremor
v. Available in immediate-release (valproic acid [Depakene]) capsules for three- or four-times-
daily dosing; delayed-release (enteric coated) (divalproex sodium [Depakote], valproic acid
[Stavzor]) capsules and tablets for twice-daily dosing (if patient on enzyme inducer, drug is
dosed more often); and extended-release (divalproex sodium [Depakote ER]) tablets for once-
daily dosing
vi. Nonepileptic indications: Manic episodes associated with bipolar disorder, prophylaxis of
migraine headaches
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-99
Neurology
w. Vigabatrin (Sabril)
i. Mechanism of action: Irreversible inhibition of γ-aminobutyric acid transaminase
ii. Pharmacokinetics: Induces CYP2C9; renal elimination
iii. Adverse effects: Fatigue, somnolence, nystagmus, tremor, blurred vision, vision impairment,
weight gain, arthralgia, abnormal coordination, and confusional state
iv. Serious adverse effect: Vision loss; increased risk with higher total dose and duration; periodic
vision testing necessary; restricted distribution program; only used for refractory complex
partial seizures and infantile spasms
x. Available as oral powder for solution
y. Zonisamide (Zonegran)
i. Mechanism of action: Fast sodium channel blocker, blocks T-type calcium currents, weak
carbonic anhydrase inhibitor
ii. Non-arylamine sulfonamide: Avoid in sulfa-sensitive patients; it is sometimes used in patients
with nonserious sulfa allergies, particularly when non-arylamine sulfonamides (i.e., sulfony-
lureas) have been used successfully.
iii. Pharmacokinetics: Long half-life
iv. Adverse effects: Depression, rash, psychomotor slowing, paresthesias, kidney stones, blood
dyscrasias, hyperthermia (associated with decreased perspiration, or oligohidrosis)
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-100
Neurology
2. Surgery: Surgery can sometimes drastically reduce the number of seizures; possible surgical procedures
include removal of the seizure focus, corpus callosotomy, or implantation of vagus nerve stimulators.
3. Status epilepticus
a. Treatment principles
i. Ascertain ABCs (airway, breathing, and circulation).
ii. Laboratory values (fingerstick blood glucose, complete blood cell count, basic metabolic
panel, calcium, magnesium, and seizure medicine serum concentrations, if applicable) are
sent to determine any reversible causes of status epilepticus.
iii. Give an emergent medication to stop the seizure immediately.
iv. Follow with an urgent medication to prevent the recurrence of seizures.
v. In general, all drugs for status epilepticus should be given parenterally.
vi. Neuromuscular-blocking drugs do not stop seizures; they stop only the muscular response to
the brain’s electrical activity.
b. Emergency medications
i. Lorazepam: Drug of choice
(a) Rapid onset (2–3 minutes)
(b) Dosage 0.1 mg/kg (up to 4 mg/dose) at rate of up to 2 mg/minute; may repeat every 5–10
minutes
ii. Diazepam
(a) Rapid onset, short duration
(b) Dosage 0.15 mg/kg (up to 10 mg/dose) at rate of up to 5 mg/minute. May repeat every
5 minutes
(c) Rectal gel formulation can be given in absence of intravenous access.
iii. Midazolam: Preferred for intramuscular administration
(a) Rapid onset, short duration
(b) Dosage 0.2 mg/kg (up to 10 mg/dose). Can be given intramuscularly, intranasally, or
buccally
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-101
Neurology
c. Urgent medications
i. Phenytoin: Dosage 20 mg/kg; administration rate less than 50 mg/minute
ii. Fosphenytoin: Administration rate less than 150 mg of phenytoin equivalent per minute
iii. Phenobarbital: Dosage 20 mg/kg at 50–100 mg/minute
iv. Valproic acid: Dosage 20–40 mg/kg at up to 6 mg/kg/minute; does not have FDA-labeled
approval for status epilepticus
v. Levetiracetam: 20–30 mg/kg over 15 minutes; does not have FDA-labeled approval for status
epilepticus
vi. Lacosamide: 200- to 400-mg bolus over 15 minutes; does not have FDA-labeled approval for
status epilepticus
d. Refractory status epilepticus medications
i. Pentobarbital: Load 5–15 mg/kg up to 50 mg/minute; follow with a 0.5- to 5-mg/kg/hour
infusion.
(a) May have severe hypotension, necessitating treatment with vasopressors; should have
continuous blood pressure measurement
(b) Must be on ventilator
ii. Thiopental: Load 2–7 mg/kg up to 50 mg/minute; follow with 0.5- to 5-mg/kg/hour infusion.
(a) May have severe hypotension, respiratory depression, cardiac depression
(b) Must be on ventilator
iii. Midazolam: Load 0.2-mg/kg infused up to 2 mg/minute; follow with a 0.05- to 2-mg/kg/hour
infusion.
(a) May have hypotension, respiratory depression
(b) May have tachyphylaxis
iv. Propofol: Load a 1- to 2-mg/kg intravenous bolus for 30–60 seconds; follow with a 20- to
200-mcg/kg/minute infusion.
(a) Significant source of lipids
(b) Some reports of seizure exacerbation with propofol
(c) Must be on ventilator
4. Special populations
a. Older adults: Pharmacokinetic changes in older adults that may affect seizure medications include
the following:
i. Carbamazepine: Decreased clearance
ii. Phenytoin: Decreased protein binding if hypoalbuminemic or in renal failure
iii. Valproic acid: Decreased protein binding
iv. Diazepam: Increased half-life
v. Phenylethylmalonamide (active metabolite of primidone): Decreased clearance if CrCl is
decreased
vi. Lamotrigine: Decreased clearance
vii. Seizure medications with renal elimination must be adjusted according to the CrCl value.
b. Women’s health
i. During their reproductive years, women with epilepsy should:
(a) Take the best drug for their seizure type. A recent proposal from the ILAE recommends
that women of childbearing age not be given valproic acid unless other therapies have
failed.
(b) Be treated with monotherapy, if possible.
(c) Discuss the possible decrease in hormonal contraceptive effectiveness if taking enzyme-
inducing medications (Table 6).
(d) Use folic acid supplementation with no less than 0.4 mg/day.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-102
Neurology
ii.
Three practice guidelines exist regarding epilepsy during pregnancy (relevant material
excerpted below).
(a) Avoiding valproic acid monotherapy or polytherapy during the first trimester of pregnancy
should be considered to decrease the risk of major congenital malformations, particularly
neural tube defects, facial clefts, hypospadias, and poor cognitive outcomes. Valproic
acid use has now been associated with lower IQ scores at ages 3 and 4½ (Neurology
2012;78:1207-14).
(b) To reduce the risk of major congenital malformations and poor cognitive outcomes, avoid-
ing the use of seizure medication polytherapy during pregnancy, if possible, should be
considered.
(c) Limiting the dose of valproic acid or lamotrigine during the first trimester, if possible,
should be considered to lessen the risk of major congenital malformations.
(d) Avoiding the use of phenytoin, carbamazepine, and phenobarbital, if possible; may be
considered to reduce the risk of cleft palate (phenytoin), posterior cleft palate (carbamaz-
epine), cardiac malformations (phenobarbital), and poor cognitive outcomes (phenytoin,
phenobarbital).
(e) Women with epilepsy taking seizure medications during pregnancy probably have an
elevated risk of small-for-gestational-age babies and 1-minute Apgar scores less than 7.
(f) Monitoring of lamotrigine, carbamazepine, and phenytoin serum concentrations during
pregnancy should be considered.
(g) Having levetiracetam and oxcarbazepine (as the monohydroxy derivative) serum concen-
trations monitored during pregnancy may be considered.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-103
Neurology
E. Other Issues
1. Starting therapy after a first seizure
a. Guidance from the American Epilepsy Society and the American Academy of Neurology
b. Adults with an unprovoked first seizure (e.g., not meningitis, intoxication) will have a 21%–45%
chance of having more seizures within the next 2 years. Higher risks are associated with prior brain
insults, EEG with epileptiform abnormalities, and nocturnal seizures.
c. Starting antiepileptic drug (AED) therapy will probably reduce recurrence risk within the first
2 years but may not increase quality of life.
d. Starting AED therapy early does not change long-term risk of seizures.
2. Driving: All states place driving restrictions on people with epilepsy; some require mandatory physi-
cian reporting to the state department of transportation.
3. Medication discontinuation
a. The American Academy of Neurology has a practice guideline (Neurology 1996;47:600-2 [http://
aan.com/professionals/practice/pdfs/gl0007.pdf]) with the following criteria for withdrawal:
i. Patient should be seizure free for 2–5 years on seizure medication.
ii. Patient should have a single type of partial or primary generalized tonic-clonic seizures.
iii. Patient should have a normal neurologic examination and normal IQ.
iv. Patient’s EEG should have become normalized with seizure medication treatment.
b. If a drug is discontinued, it is usually tapered for several months; a typical regimen would reduce the
dose by one-third for 1 month, reduce it by another one-third for 1 month, and then discontinue it.
4. Monitoring
a. Number of seizures: The goal number of seizures is always zero.
b. Signs of toxicity
c. Laboratory values: Specific for each drug
d. Blood concentrations: Available for many of the medications, commonly used for carbamazepine,
phenobarbital, phenytoin, and valproic acid. The ILAE has a position paper on therapeutic drug
monitoring, giving situations in which serum concentrations are most likely to be of benefit:
i. When a person has attained the desired clinical outcome, to establish an individual therapeutic
concentration that can be used subsequently to assess potential causes for a change in drug
response
ii. As an aid in the diagnosis of clinical toxicity
iii. To assess adherence, particularly in patients with uncontrolled seizure or breakthrough
seizures
iv. To guide dosage adjustment in situations associated with increased pharmacokinetic variabil-
ity (e.g., children, older adults, patients with associated diseases, drug formulation changes)
v. When a potentially important pharmacokinetic change is anticipated (e.g., in pregnancy, or
when an interacting drug is added or removed)
vi. To guide dose adjustments for seizure medications with dose-dependent pharmacokinetics,
particularly phenytoin
5. Sexual dysfunction
a. Described in 30%–60% of men and women with epilepsy
b. Includes hyposexuality, orgasmic dysfunction, and erectile dysfunction
c. Mechanism may be induction of CYP isoenzymes to increase testosterone metabolism, increased
hepatic synthesis of sex hormone–binding globulin, or induction of aromatase, which converts free
testosterone to estradiol.
d. Sexual dysfunction has been reported with carbamazepine, phenobarbital, phenytoin, pregabalin,
topiramate, and zonisamide.
e. Improved sexual functioning has been reported with lamotrigine and oxcarbazepine.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-104
Neurology
6. Bone health
a. Osteopenia or osteoporosis is found in 38%–60% of patients in tertiary epilepsy clinics.
b. Increased fractures in patients with epilepsy and with seizure medication use
c. Risk is increased with increased treatment duration; there is a dose-response relationship; the med-
ications most often associated with poor bone health are carbamazepine, clonazepam, phenobarbi-
tal, phenytoin, and valproic acid. However, there is now evidence that all seizure medications may
contribute to osteopenia or osteoporosis.
d. Proposed mechanisms: Hepatic induction of CYP isoenzymes leads to increased vitamin D catab-
olism, impaired calcium absorption, calcitonin deficiency, vitamin K interference, and direct
detrimental effect on bone cells.
e. Proposed treatments: High-dose vitamin D (4000 international units/day for adults and 2000 inter-
national units/day for children) improves bone mineral density compared with low doses; estrogen
may be helpful for women but may also trigger seizures in some women.
7. Suicidality
a. Meta-analysis of 199 placebo-controlled clinical trials of 11 drugs (n=43,892 patients older than
5 years) showed patients who received seizure medications had about twice the risk of suicidal
behavior or ideation (0.43%) compared with patients receiving placebo (0.22%), and there were
four completed suicides in the treatment group versus zero in the placebo group.
i. Risk increased at 1 week and continued through week 24.
ii. Patients with epilepsy (relative risk [RR] = 3.6), psychiatric disorders (RR = 1.6), or other
conditions (RR = 2.3) were all at elevated risk of suicidality; no differences between drugs; no
differences between age groups
b. The FDA requires a warning and a medication guide for all seizure medications.
c. Recent observational studies show mixed results. When specific AEDs are examined, the ones
most associated with depression and suicidality are levetiracetam, perampanel, phenobarbital,
primidone, tiagabine, topiramate, and vigabatrin.
d. An expert consensus statement was released in 2013 making the following points:
i. Although some (but not all) AEDs can be associated with treatment-emergent psychiatric
problems that may lead to suicidal ideation and behavior, the actual suicidal risk is yet to be
established; however, it seems to be very low. The risk of discontinuing AEDs or refusing to
initiate them is significantly worse and can actually result in serious harm, including death to
the patient.
ii. Suicidality in epilepsy is multifactorial. Primary operant variables include postictal suicidal
ideation; a history of psychiatric disorders, particularly mood and anxiety disorders (and
above all, when associated with prior suicidal attempts); and a family history of mood disorder
complicated by suicide attempts.
iii. When starting or switching AEDs, patients should be advised to report any changes in mood
and suicidal ideation.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-105
Neurology
Patient Cases
Questions 1–3 pertain to the following case.
T.M. is an 18-year-old new patient in the pharmacy where you work. He presents a prescription for carbamaze-
pine 100 mg 1 tablet orally twice daily with instructions to increase to 200 mg 1 tablet orally three times daily.
Currently, he takes no medications and has no drug allergies. During your counseling session, T.M. tells you he
must have blood obtained for a test in 3 weeks.
1. Which common potential adverse effect of carbamazepine is best assessed through obtaining blood?
A. Leukopenia.
B. Renal failure.
C. Congestive heart failure.
D. Hypercalcemia.
2. One month later, T.M. returns to your pharmacy with a new prescription for lamotrigine 25 mg with instruc-
tions to take 1 tablet daily for 2 weeks, followed by 1 tablet twice daily for 2 weeks, followed by 2 tablets
twice daily for 2 weeks, and then 3 tablets twice daily thereafter. He tells you that he is discontinuing carba-
mazepine because he developed a rash a few days ago. Which response is best?
A.
The rash was probably caused by carbamazepine because carbamazepine rash often has delayed
development.
B. The rash was probably not caused by carbamazepine because carbamazepine rash usually presents after
the first dose.
C. The rash was probably not caused by carbamazepine; it is probably attributable to carbamazepine-
induced liver failure.
D The rash was probably not caused by carbamazepine; it is probably attributable to carbamazepine-
induced renal failure.
3. T.M. wants to know why it is necessary to increase the lamotrigine dose so slowly. Which reply is best?
A. Lamotrigine causes dose-related psychomotor slowing.
B. Lamotrigine causes dose-related renal stones.
C. Lamotrigine causes dose-related paresthesias.
D. Lamotrigine causes dose-related rash.
4. J.G. is a 34-year-old patient who has been maintained on carbamazepine extended release 400 mg orally
twice daily for the past 2 years. She has had no seizures for the past 4 years. She presents to the ED in status
epilepticus. Which drug is best to use first?
A. Diazepam.
B. Lorazepam.
C. Phenytoin.
D. Phenobarbital.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-106
Neurology
6. S.S. is a 22-year-old woman who has always had episodes of “zoning out.” Recently, one of these episodes
occurred after an examination while she was driving home. She had a noninjury accident, but it prompted
a visit to a neurologist. She is given a diagnosis of absence seizures. Which drug is best to treat this type
of epilepsy?
A. Phenytoin.
B. Tiagabine.
C. Carbamazepine.
D. Ethosuximide.
7. J.B. is a 25-year-old man with a history of seizure disorder. He has been treated with phenytoin 200 mg orally
twice daily for 6 months, and his current phenytoin concentration is 6.3 mcg/mL. His neurologist decides
to increase his phenytoin dose to 300 mg twice daily. Which adverse effect is J.B. most likely to experience
related to the dose increase?
A. Drowsiness.
B. Acne.
C. Gingival hyperplasia.
D. Rash.
8. M.G., a 15-year-old male adolescent with a diagnosis of juvenile myoclonic epilepsy, has been prescribed
sodium valproate. On which adverse effect is it best to counsel M.G.?
A. Oligohidrosis.
B. Renal stones.
C. Alopecia.
D. Word-finding difficulties.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-107
Neurology
10. When you see G.Z. 6 months later for a follow-up, she tells you she is about 6 weeks pregnant. She has had no
seizures since beginning drug therapy. Which strategy is best for G.Z.?
A. Discontinue her seizure medication immediately.
B. Discontinue her seizure medication immediately and give folic acid.
C. Continue her seizure medication.
D. Change her seizure medication to phenobarbital.
A. Epidemiology
1. Updated definitions
a. Central nervous system (CNS) infarction: Brain, spinal cord, or retinal cell death attributable to
ischemia, based on pathologic evidence, imaging, or other objective evidence of cerebral, spinal
cord, or retinal focal ischemic injury in a defined vascular distribution, or clinical evidence of
cerebral, spinal cord, or retinal focal ischemic injury, based on symptoms persisting for 24 hours
or more or until death, and other etiologies excluded
b. Ischemic stroke: An episode of neurologic dysfunction caused by focal cerebral, spinal, or retinal
infarction
2. Third or fourth most common cause of death in all developed countries
3. More than 795,000 cases per year in the United States (128,842 deaths)
4. Most common cause of adult disability
5. Risk factors
a. Nonmodifiable
i. Age: Stroke risk doubles each decade after 55 years.
ii. Race: Risk for Native Americans is greater than for African Americans, whose risk is greater
than for whites.
iii. Sex: Risks are greater for men than for women; however, about half of strokes occur in women.
iv. Low birth weight: Odds of stroke for those with birth weights less than 2500 g are twice has
high as the odds for those weighing more than 4000 g.
v. Family history: Parental history increases risk; some coagulopathies (e.g., protein C and S
deficiencies, factor V Leiden mutations) are inherited.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-108
Neurology
b. Somewhat modifiable: Diabetes mellitus increases risk 1.8–6 times; risk reduction has not been
shown for glycemic control.
c. Modifiable
i. Hypertension increases risk 1.4–8 times; 32% risk reduction with control
ii. Smoking increases risk 1.9 times; 50% risk reduction in 1 year, baseline risk at 5 years with
smoking cessation; exposure to environmental cigarette smoke also increases risk.
iii. Oral contraceptives with less than 50 mcg of estrogen double risk of stroke; those with more
than 50 mcg of estrogen increase risk 4.5 times; risk increases with age; adding smoking
to oral contraceptive use increases risk of stroke 7.2 times; obesity and hypertension also
increase the risk with oral contraceptives.
iv. Postmenopausal hormone therapy increases risk 1.4 times.
v. Atrial fibrillation increases risk 2.6–4.5 times; 68% risk reduction with warfarin
vi. Coronary heart disease increases risk 1.55 times (women) to 1.73 times (men).
vii. Asymptomatic carotid stenosis increases risk 2 times; about a 50% risk reduction with
endarterectomy
viii. Dyslipidemia: High total cholesterol increases risk 1.5 times; low high-density lipoprotein
cholesterol (less than 35 mg/dL) increases risk 2 times; 27%–32% risk reduction with statins
in patients with coronary heart disease, hypertension, or diabetes. Twenty-five percent risk
reduction with high-dose statins compared with low-dose statins
ix. Obesity (especially abdominal body fat) increases risk 1.75–2.37 times; risk reduction with
weight loss is unknown.
x. Physical inactivity increases risk 2.7 times; risk reduction with increased activity is unknown.
xi. Sickle cell disease increases risk 200–400 times; 91% risk reduction with transfusion therapy
xii. Peripheral artery disease increases risk 3 times; impact of risk reduction strategies is unknown.
xiii. Pregnancy increases risk 2.4 times over nonpregnant women; the risk remains elevated for the
first 6 weeks postpartum.
xiv. Patent foramen ovale increases the risk of stroke in young patients (younger than 55 years).
xv. Depression increases the risk of stroke 1.35 times compared with nondepressed people.
d. Less well documented: Alcohol abuse (5 or more drinks a day), hyperhomocystinemia, drug abuse
(cocaine, amphetamines, and heroin), hypercoagulability, periodontal disease, inflammation and
infection, sleep-disordered breathing (sleep apnea and snoring), metabolic syndrome, and migraine
with aura
B. Primary Prevention
1. Reduction in risk factors (e.g., control of hypertension, smoking cessation, control of diabetes, choles-
terol reduction)
2. Patient education: Patients should be educated about stroke warning signs and instructed to seek emer-
gency care if they have any of them. Warning signs: Sudden numbness or weakness of the face, arm, or
leg, especially on one side of the body; sudden confusion; trouble speaking or understanding; sudden
trouble seeing in one or both eyes; sudden trouble walking; dizziness, loss of balance or coordination;
sudden, severe headache with no known cause
3. Treatment of atrial fibrillation: Up to 70% of cases are inappropriately treated.
a. Recommendations based on Chest 2012;141:e601S-36S (http://journal.publications.chestnet.org/
pdfaccess.ashx?ResourceID=6568275&PDFSource=13); Chest 2012;141:e531S-75S (http://journal.
publications.chestnet.org/pdfaccess.ashx?ResourceID=6568280&PDFSource=13); Neurology
2014;82:716-24 (www.neurology.org/content/82/8/716.full); Stroke 2014;45:3754-832 (http://stroke.
ahajournals.org/content/45/12/3754).
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-109
Neurology
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-110
Neurology
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-111
Neurology
D. Secondary Prevention
1. Reduction in all modifiable risk factors (specific changes below based on Stroke 2014;45:2160-236 [http://
stroke.ahajournals.org/content/45/7/2160.full.pdf+html?sid=0efbdc13-bba8-4e90-b197-d58dd042f816])
a. Hypertension: Goal less than 140/ 90 mm Hg. With lacunar stroke, may target less than 130 mm
Hg systolic
b. Hyperlipidemia: High-intensity statin therapy should be initiated or continued as first-line therapy
in women and men less than 75 years of age who have had stroke or TIA.
2. Carotid endarterectomy if 70%–99% stenosis. For 50%–69% stenosis, carotid endarterectomy recom-
mendation depends on age, sex, and comorbidities; use aspirin 50–100 mg/day and statin therapy before
and after the procedure.
3. Carotid angioplasty and stenting may be an alternative to carotid endarterectomy in some patients,
particularly younger patients.
4. Antiplatelet therapy: Each agent has shown efficacy in reducing secondary stroke risk. Guidelines dif-
fer slightly on their recommendations. The American Stroke Association suggests that aspirin, aspi-
rin/extended-release dipyridamole, and clopidogrel are all options after a first stroke or TIA, and the
combination of aspirin and clopidogrel might be considered for initiation within 24 hours of a minor
ischemic stroke or TIA or in the setting of intracranial atherosclerotic disease and continued for 90
days; however, long-term treatment increases risk of hemorrhage. The American Association of Chest
Physicians recommends clopidogrel or aspirin/dipyridamole over aspirin or cilostazol.
a. Aspirin
i. Dose: 75–100 mg/day
ii. If the patient has an additional stroke while taking aspirin, there is no evidence that increasing
the aspirin dose will provide additional benefit.
b. Aspirin/dipyridamole (Aggrenox)
i. Capsule contains dipyridamole extended-release pellets (200 mg) and aspirin tablet (25 mg).
ii. Dose: 1 capsule orally twice daily
iii. Most common adverse effects: Headache, nausea, and dyspepsia; can increase liver enzymes
c. Clopidogrel (Plavix)
i. Inhibits adenosine diphosphate–induced platelet aggregation
ii. Dose: 75 mg/day orally
iii. Very low incidence of neutropenia (0.04% severe)
iv. Rarely, thrombotic thrombocytopenic purpura has been reported.
v. Partly metabolized by CYP2C19; there may be interactions with inhibitors of CYP2C19, notably
proton pump inhibitors, or with genetic polymorphisms of this enzyme. The FDA has issued
an alert on this topic (www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor
PatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm190787.htm).
d. Cilostazol (Pletal)
i. Inhibits cyclic adenosine monophosphate phosphodiesterase type 3–induced platelet aggregation
ii. Dose: 100 mg orally twice daily on an empty stomach
iii. Metabolized extensively by CYP3A4 and CYP2C19
iv. Adverse effects: Headache, palpitation, diarrhea, and dizziness; rarely, thrombocytopenia or
agranulocytosis. Contraindicated in patients with congestive heart failure
v. Monitoring: Complete blood cell count with differential every 2 weeks for 3 months, periodi-
cally thereafter. Thus, used infrequently
5. Anticoagulation: Warfarin (Athrombin-K, Coumadin, Jantoven, Panwarfin)
a. Prevention of second ischemic event, if patient has atrial fibrillation, rheumatic mitral valve disease,
mechanical prosthetic heart valves, bioprosthetic heart valves, or left ventricular mural thrombus
formation
b. Target INR of 2.5 (3.0 for mechanical prosthetic heart valves)
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-112
Neurology
Patient Cases
Questions 11–13 pertain to the following case:
L.R. is a 78-year-old man who presents to the ED for symptoms of right-sided paralysis. He states that these
symptoms began about 5 hours ago and have not improved since then. He also has hypertension, benign prostatic
hypertrophy, diabetes mellitus, erectile dysfunction, and osteoarthritis.
11. Which is the most accurate list of L.R.’s risk factors for stroke?
A. Erectile dysfunction, age, osteoarthritis.
B. Sex, diabetes mellitus, osteoarthritis.
C. Benign prostatic hypertrophy, diabetes mellitus, age, sex.
D. Age, diabetes mellitus, sex, hypertension.
12. Which best describes whether L.R. is a candidate for tissue plasminogen activator for treatment of stroke?
A. Yes.
B. No, he is too old.
C. No, his stroke symptoms began too long ago.
D. No, diabetes mellitus is a contraindication for tissue plasminogen activator.
13. L.R. previously took no drugs at home. Which choice is the best secondary stroke prevention therapy for this
patient?
A. Sildenafil.
B. Celecoxib.
C. Aspirin.
D. Warfarin.
14. You are the pharmacist at a community pharmacy and receive a call from M.W., a 60-year-old man recently
given a diagnosis of atrial fibrillation. He is concerned about his risk of having a stroke because his friend,
who also has atrial fibrillation, asked him which dose of warfarin he is taking. M.W. called you because he is
not taking warfarin and wants to know whether he should. He has no other medical conditions and takes aten-
olol 50 mg/day orally for ventricular rate control. After encouraging M.W. to discuss this with his physician,
which is best to tell him?
A. You need warfarin treatment to prevent a stroke.
B. You do not need warfarin, but you should take aspirin and clopidogrel.
C. You do not need drug therapy at this time.
D. Because you have atrial fibrillation, nothing can reduce your risk of stroke.
15. L.S. is a 72-year-old woman with a medical history of hypertension, type 2 diabetes, renal failure, and atrial
fibrillation. She presents to the anticoagulation clinic for her initial visit. Which best reflects her target INR?
A. 1.5.
B. 2.0.
C. 2.5.
D. 3.0.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-113
Neurology
A. Epidemiology
1. Prevalence is 160 in 100,000.
2. Onset usually at 40–70 years of age, with peak onset in sixth decade
3. Slightly more common in men
4. Observed in all countries, ethnic groups, and socioeconomic classes
C. Treatment
1. General treatment principles
a. No treatment has been unequivocally shown to prevent progression of Parkinson disease; therefore,
treatment is based on symptoms.
b. In patients who need to be initiated on dopaminergic treatment, either levodopa or a dopamine
agonist may be used. The choice depends on the relative impact of improving motor disability
(better with levodopa) compared with the lessening of motor complications (better with dopamine
agonists) for each individual patient.
c. Treatment may be initiated with rasagiline as well, but the effects are not robust.
d. Treatment with several different classes of medications simultaneously is common.
2. Medications
a. Monoamine oxidase type B (MAO-B) inhibitors
i. Selegiline (Eldepryl, Zelapar)
(a) Loses selectivity for MAO-B at doses greater than 10 mg/day
(b) Contraindicated with meperidine because of serotonin syndrome risk
(c) Dose: 5 mg orally twice daily (tablets; usually morning and noon); 1.25–2.5 mg/day (orally
disintegrating tablets)
(d) Adverse effects: Nausea, hallucinations, orthostatic hypotension, insomnia (metabolized
to amphetamine)
(e) Dosage forms: Tablets, orally dissolving tablets, and patches. The patches are FDA indi-
cated for depression; they should not usually be used to treat Parkinson disease.
ii. Rasagiline (Azilect)
(a) Selectivity for MAO-B has not been definitively established.
(1) Contraindicated with meperidine because of serotonin syndrome risk
(2) Do not administer with tramadol, methadone, dextromethorphan, sympathomimet-
ics, fluoxetine, or fluvoxamine because of serotonin syndrome risk.
(3) Ciprofloxacin can double the concentration of rasagiline (through CYP1A2 inhibition).
(b) Dose: 0.5–1 mg/day orally
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-114
Neurology
b. Levodopa
i. Improvement in disability and possibly mortality
ii. Greatest effect on bradykinesia and rigidity; less effect on tremor and postural instability
c. Carbidopa
i. Combined in fixed ratios with levodopa
ii. Prevents some of the peripheral conversion of levodopa to dopamine by inhibiting peripheral
dopamine decarboxylase; therefore, levodopa is available to cross the blood-brain barrier
iii. 75 mg/day is usually needed to inhibit peripheral decarboxylase activity.
d. Carbidopa/levodopa (Carbilev, Parcopa, Sinemet)
i. Pharmacokinetic considerations
(a) High-protein diets decrease absorption.
(b) Immediate-release half-life 60–90 minutes
(c) Orally disintegrating tablet available; not absorbed sublingually
(d) Slow-release considerations: Fewer daily doses; less plasma fluctuations; delay to effect;
cannot crush; can divide. No measurable effect on “freezing”
ii. Acute adverse effects: Nausea and vomiting, orthostatic hypotension, cardiac arrhythmias,
confusion, agitation, hallucinations
iii. Long-term adverse effects: Wearing-off and on-off phenomena, involuntary movements
(dyskinesias)
(a) Wearing-off phenomenon is the return of Parkinson disease symptoms before the next
dose. Treatment of wearing-off includes adding a dopamine agonist, adding a MAO-B
inhibitor, adding a catechol-O-methyl transferase (COMT) inhibitor, or increasing the
frequency or dose of levodopa.
(b) On-off phenomenon is a profound, unpredictable return of Parkinson disease symptoms
without respect to the dosing interval. Treatment of on-off includes adding entacapone,
rasagiline, pramipexole, ropinirole, apomorphine, and selegiline or redistributing dietary
protein.
(c) Dyskinesias are drug-induced involuntary movements including chorea and dystonia.
Treatment of dyskinesias includes decreasing the levodopa dose or adding amantadine as
an antidyskinetic drug.
iv. Therapy initiation
(a) Standard formulation: 25 mg/100 mg 1 tablet orally three times daily; also available as
orally disintegrating tablet
(b) Controlled-release formulation: 1 tablet orally two or three times daily
(c) Titration always necessary
(d) A combination of formulations may be needed (e.g., ½ tablet of Sinemet 25 mg/100 mg on
awakening and 1 tablet of Sinemet CR 25/100 three times daily).
e. Direct dopamine agonists
i. Drugs: Apomorphine (Apokyn), bromocriptine (Parlodel), pramipexole (Mirapex), ropinirole
(Requip), rotigotine (Neupro)
ii. Bromocriptine is an ergot-derived product: Very rarely, adverse effects such as retroperito-
neal, pleuropulmonary, or cardiac fibrosis have been attributed to it; regular monitoring of the
electrocardiogram is recommended.
iii. Rotigotine is a transdermal system. With the initial formulation, problems occurred with
crystallization of the medication. The product was withdrawn from the market and has since
been reformulated.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-115
Neurology
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-116
Neurology
g. Amantadine (Symmetrel)
i. Has symptomatic benefits and may reduce dyskinesias caused by levodopa or dopamine
agonists
ii. Dosing: 100 mg 1 tablet orally two or three times daily; caution in renal dysfunction
iii. Adverse effects: Dizziness, insomnia, anxiety, livedo reticularis, nausea, nightmares
h. COMT inhibitors
i. Prevent breakdown of dopamine, more levodopa available to cross blood-brain barrier
ii. Tolcapone (Tasmar): Severely restricted because of hepatotoxicity; must sign consent form
iii. Entacapone (Comtan)
(a) Increased area under the curve, increased half-life; no change in Cmax or Tmax of
levodopa
(b) Dosing: 1 tablet with each carbidopa/levodopa dose; maximum of eight times daily; one
dosage form (Stalevo) includes carbidopa, levodopa, and entacapone 200 mg
(c) Must use with carbidopa/levodopa
(d) Adverse effects: Dyskinesias, nausea, diarrhea (may be delayed for up to 2 weeks after
initiation or dose increase), urine discoloration (orange), hallucinations or vivid dreams
3. Surgery: Several types of surgery are performed for Parkinson disease.
a. Thalamotomy: Ablation of portions of the thalamus to control tremor
b. Pallidotomy: Ablation of structures in the globus pallidus for the treatment of Parkinson disease
c. Fetal transplants: Transplantation of dopaminergic tissue into the striatum; considered experimental
d. Trophic factors: Glial-derived nerve growth factor and neurturin have been delivered directly to
the striatum or substantia nigra; considered experimental
e. Deep brain stimulation
i. Most commonly performed surgery for Parkinson disease
ii. Thought to work by stimulating areas of the basal ganglia to reversibly block the neuronal
activity in the area
iii. Patient selection focuses on patients with
(a) Motor fluctuations or dyskinesias that are not adequately controlled with optimized
medical therapy
(b) Medication-refractory tremor
(c) Intolerance of medical therapy
(d) Some centers will not perform the surgery in patients older than 70 years.
iv. Two areas are targeted.
(a) Globus pallidum
(1) Reduces off-time
(2) Reduces dyskinesias
(3) Thought to have fewer cognitive adverse effects than subthalamic nucleus stimulation
(b) Subthalamic nucleus
(1) Reduces off-time
(2) Reduces dyskinesias
(3) Thought to be more effective than globus pallidum stimulation
4. Special situations
a. Hallucinations or psychosis may be caused by either Parkinson disease or treatment.
i. Discontinue or reduce Parkinson disease medications as tolerated.
ii. If an antipsychotic is needed, use quetiapine or clozapine as the first choice.
iii. Avoid typical antipsychotics, risperidone, and olanzapine because they may worsen Parkinson
symptoms.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-117
Neurology
b. Cognitive disorders
i. Discontinue or reduce Parkinson disease medications as tolerated.
ii. Rivastigmine has an FDA indication for treatment; other cholinesterase inhibitors may have
efficacy.
c. Sleep disorders, depression, agitation, anxiety, constipation, orthostatic hypotension, seborrhea,
and blepharitis can be seen in Parkinson disease; treat as usual.
Patient Cases
Questions 16 and 17 pertain to the following case.
L.S. takes carbidopa/levodopa 25 mg/100 mg orally four times daily and trihexyphenidyl 2 mg orally three times
daily for Parkinson disease. L.S.’s wife reports that he is often confused and has constipation; he has trouble
talking because of his dry mouth.
17. Six months later, L.S. returns to the clinic concerned that his carbidopa/levodopa dose is wearing off before
his next dose is due. Which recommendation is best?
A. Increase the carbidopa/levodopa dose.
B. Decrease the carbidopa/levodopa dose.
C. Increase the dosing interval.
D. Decrease the dosing interval.
18. P.J. is a 57-year-old man with an 8-year history of Parkinson disease. His current drugs include carbidopa/
levodopa 50 mg/200 mg orally four times daily, entacapone 200 mg orally four times daily, and amantadine
100 mg three times daily. He presents to the clinic with a reddish blue discoloration on his lower arms and
legs. Which, if any, of his drugs is the most likely cause of this condition?
A. Carbidopa/levodopa.
B. Entacapone.
C. Amantadine.
D. None; probably represents venous stasis.
19. L.L. is a 47-year-old man with Parkinson disease. He takes carbidopa/levodopa 50 mg/200 mg orally four
times daily. He recently noticed an involuntary twitching movement of his left foot. Which is the best therapy
for L.L.’s dyskinesia?
A. Add ropinirole.
B. Add selegiline.
C. Increase the carbidopa/levodopa dose.
D. Decrease the carbidopa/levodopa dose.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-118
Neurology
IV. HEADACHE
A. Definitions
1. Classic migraine: At least two attacks with at least three of the following: One or more fully reversible
aura symptoms, at least one aura symptom for more than 4 minutes, or two or more symptoms occur-
ring in succession; no single aura symptom lasts more than 60 minutes; headache follows aura within
60 minutes.
2. Migraine without aura: At least five attacks of headache lasting 4–72 hours with at least two of the
following: Unilateral location, pulsating quality, intensity moderate or severe, aggravation by walking
stairs or similar routine physical activity. During headache, at least one of the following: Nausea or
vomiting, photophobia, phonophobia
3. Tension: At least 10 previous headaches, each lasting from 30 minutes to 7 days, with at least two of the
following: Pressing or tightening (nonpulsating) quality, intensity mild to moderate, bilateral location,
no aggravation with physical activity
4. Cluster: Several episodes, short-lived but severe, of unilateral, orbital, supraorbital, or temporal pain. At
least one of the following must occur: Conjunctival injection, lacrimation, nasal congestion, rhinorrhea,
facial sweating, miosis, ptosis, or eyelid edema.
5. Analgesic rebound headache: If patients use analgesics often (usually defined as more than three times
weekly), they may develop analgesic rebound headache. Patients with this condition usually present
with a chronic daily headache, for which they take simple or narcotic analgesics. Treatment consists of
withdrawing all analgesics (but not prophylactic medications).
B. Epidemiology
1. Migraine: 15%–17% of women, 5% of men
2. Tension: 88% of women, 69% of men
3. Cluster: 0.01%–1.5% of population; ratio of men to women is 6:1.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-119
Neurology
C. Treatment
1. Migraine
a. Prophylaxis should be considered if any of the following criteria are met: Migraines are recurrent
and interfere with daily routine, migraines are frequent, patient has inefficacy or inability to use
acute therapy, patient prefers prophylaxis as therapy, cost of acute medications is problematic,
adverse effects with acute therapies occur, or migraine presentation is uncommon.
i. General principles
(a) Use lowest effective dose.
(b) Give adequate trial (2–3 months).
(c) If patient has a coexisting condition, consider prophylaxis choice (e.g., β-blockers are
contraindicated in patients with asthma but beneficial in hypertension).
ii. Medications with established efficacy
(a) Frovatriptan (for menstrually associated migraine, short-term prophylaxis only)
(b) Metoprolol
(c) Onabotulinum toxin A
(d) Petasites (butterbur extract)
(e) Propranolol
(f) Timolol
(g) Topiramate
(h) Valproic acid
iii. Medications with probable efficacy
(a) Amitriptyline
(b) Atenolol
(c) Fenoprofen
(d) Histamine, subcutaneous
(e) Ibuprofen
(f) Ketoprofen
(g) Magnesium
(h) MIG-99 (feverfew extract)
(i) Nadolol
(j) Naproxen/naproxen sodium
(k) Naratriptan (for menstrually associated migraine, short-term prophylaxis only)
(l) Riboflavin
(m) Venlafaxine
(n) Zolmitriptan (for menstrually associated migraine, short-term prophylaxis only)
iv. Medications with possible efficacy
(a) Candesartan
(b) Carbamazepine
(c) Clonidine
(d) Coenzyme Q10
(e) Cyproheptadine
(f) Estrogen
(g) Flurbiprofen
(h) Guanfacine
(i) Lisinopril
(j) Mefenamic acid
(k) Nebivolol
(l) Pindolol
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-120
Neurology
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-121
Neurology
3. Cluster
a. Prophylaxis
i. Verapamil
ii. Melatonin
iii. Suboccipital injection of betamethasone
iv. Lithium: May be efficacious at serum concentrations as low as 0.3 mmol/L
b. Treatment
i. Triptans: Subcutaneous and intranasal sumatriptan and intranasal zolmitriptan are effective.
Oral formulations usually do not act quickly enough, but oral zolmitriptan showed efficacy in
one trial.
ii. Oxygen: 100% oxygen at 6–12 L/minute relieves pain in 50%–85% of patients.
iii. Intranasal lidocaine: 20–60 mg as a nasal drop or spray (must be compounded)
iv. Octreotide and 10% cocaine have been used with some effect.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-122
Neurology
Patient Cases
21. M.R., a 34-year-old woman, has throbbing right-sided headaches. She experiences nausea, sonophobia, and
photophobia with these headaches but no aura. She usually has headaches twice a month. She is hyperten-
sive and morbidly obese. She takes an ethinyl estradiol/progestin combination oral contraceptive daily and
hydrochlorothiazide 25 mg/day orally. She has a diagnosis of migraine headaches. Which medication is best
for prophylaxis of her headaches?
A. Propranolol.
B. Valproic acid.
C. Amitriptyline.
D. Lithium.
22. S.R. is a 54-year-old female homemaker with squeezing, bandlike headaches that occur three or four times
weekly. She rates the pain of these headaches as 7/10 and finds acetaminophen, aspirin, ibuprofen, naproxen,
ketoprofen, and piroxicam only partly effective. She wants to take a prophylactic drug to prevent these
tension headaches. Which drug is best for prophylaxis of her headaches?
A. Propranolol.
B. Valproic acid.
C. Amitriptyline.
D. Lithium.
23. D.S. is a 49-year-old male computer programmer who describes lancinating right-eye pain and tearing several
times a day for 2–3 days in a row. He will have no episodes for 2–3 weeks but then will have recurrent epi-
sodes. In the office, he receives oxygen by nasal cannula during an episode, and his pain is relieved. He has a
diagnosis of cluster headaches. Which drug is best for prophylaxis of his headaches?
A. Propranolol.
B. Valproic acid.
C. Amitriptyline.
D. Lithium.
24. M.K. is a 44-year-old woman with right-sided headaches of moderate intensity that are accompanied by
severe nausea and vomiting. Which triptan is best to treat M.K.’s migraine headaches?
A. Almotriptan.
B. Naratriptan.
C. Rizatriptan.
D. Sumatriptan.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-123
Neurology
Drug NNT
Ergotamine + caffeine 6.6
Eletriptan 80 mg 2.8
Rizatriptan 10 mg 5.6
Sumatriptan 50 mg 6.0
V. MULTIPLE SCLEROSIS
A. Definitions
1. Autoimmune disorder with areas of CNS demyelination and axonal transaction
2. Clinical course
a. Clinically isolated syndrome; first clinical presentation for which the criterion of dissemination in
time has not been met to diagnose multiple sclerosis (MS)
b. Classified as relapsing or progressive disease; subclassified according to disease activity and pro-
gression: Relapsing-remitting: 85% of patients at diagnosis, develops into progressive disease in
50% of patients within 10 years
B. Epidemiology
1. Diagnosis usually at 20–50 years of age
2. Twice as many women as men develop multiple sclerosis.
3. Whites and people of northern European heritage are more likely to develop MS.
4. Risk factors: Family history of MS, autoimmune disease, or migraine; personal history of autoimmune
disease or migraine; cigarette smoke exposure (women only)
C. Treatment
1. Acute relapses are treated with corticosteroids.
a. Intravenous methylprednisolone: The usual dose is 1 g/day as one dose or divided doses for 3–5
days.
b. Oral prednisone: The usual dose is 1250 mg/day given every other day for five doses.
c. Intravenous adrenocorticotropic hormone
d. Neurologic recovery is the same with or without an oral prednisone taper.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-124
Neurology
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-125
Neurology
e. Fingolimod (Gilenya)
i. Mechanism of action: Binds to the S1P receptor 1 expressed on T cells, prevents activation of
T cells
ii. Contraindicated in patients with myocardial infarctions, unstable angina, stroke, TIAs, or
decompensated heart failure necessitating hospitalization or class III/IV heart failure, history
of Mobitz type II second- or third-degree atrioventricular block or sick sinus syndrome unless
patient has a pacemaker, baseline QTc interval greater than or equal to 500 milliseconds, or
treatment with class Ia or class III antiarrhythmic drugs
iii. Patients must be monitored for bradycardia for 6 hours after the first dose; if therapy is discon-
tinued for more than 2 weeks, patients must be re-monitored.
iv. Adverse effects
(a) Bradycardia: Electrocardiogram is recommended within 6 months for patients using anti-
arrhythmics (including β-blockers and calcium channel blockers), those with cardiac risk
factors, and those with slow or irregular heartbeat. Heart rate returns to baseline within
1 month of continued dosing.
(b) Atrioventricular conduction delays: First- and second-degree block
(c) Decrease in lymphocytes: A recent complete blood cell count should be available before
therapy starts. Infections may be more common. Discontinue therapy for serious infections;
test patients without varicella zoster vaccine or infection history for varicella zoster virus
antibodies, and immunize antibody-negative patients (wait 1 month to begin fingolimod).
(d) Macular edema: Ophthalmologic evaluation at baseline and 3–4 months after fingolimod
initiation; a history of uveitis or diabetes mellitus increases risk.
(e) Respiratory effects: Decreases in forced expiratory volume over 1 second and diffusion
lung capacity for carbon monoxide can occur.
(f) Elevation of liver enzymes
(g) Hypertension: Monitor during treatment.
(h) Extended effects of drug for up to 2 months after discontinuation necessitate extended
monitoring for many adverse effects.
v. Drug interactions
(a) Ketoconazole: Increased fingolimod
(b) Vaccines: Less effective during and 2 months after fingolimod treatment; avoid live,
attenuated vaccines
vi. Avoid pregnancy during treatment and for 2 months after treatment.
f. Mitoxantrone (Novantrone)
i. Mechanism of action: Decreases monocytes and macrophages, inhibits T and B cells
ii. Indicated for secondary progressive, progressive-relapsing, and worsening-relapsing-
remitting multiple sclerosis; used infrequently because of toxicity
iii. Because of the potential for toxicity, mitoxantrone is reserved for patients with rapidly advanc-
ing disease whose other therapies have failed.
iv. Patients taking mitoxantrone should not receive live virus vaccines; other vaccines should
be held for 4–6 weeks after dose.
v. Cardiotoxicity: Echocardiograms or multiple-gated acquisition scans must be performed at
baseline and before each infusion. Systolic dysfunction occurs in about 12% of patients; con-
gestive heart failure occurs in about 0.4%. Cardiotoxicity is not dose-, sex-, or age-related.
Cyclooxygenase 2 inhibitors should be avoided.
vi. Therapy-related acute leukemia occurs in about 0.8% of patients.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-126
Neurology
vii. Other laboratory tests (complete blood cell count, bilirubin, aspartate aminotransferase, ala-
nine aminotransferase, alkaline phosphatase, and pregnancy test) must be performed before
each infusion.
viii. Avoid pregnancy during treatment.
g. Natalizumab (Tysabri)
i. Mechanism of action: Block T-cell entry into the CNS
ii. Indicated for relapsing forms of multiple sclerosis but distributed through restricted distribu-
tion program because of progressive multifocal leukoencephalopathy risk (0.24%)
iii. Adverse effects
(a) Hypersensitivity reactions: Itching, dizziness, fever, rash, hypotension, dyspnea, chest
pain, anaphylaxis, usually within 2 hours of administration
(b) Progressive multifocal leukoencephalopathy: Rapidly progressive viral CNS infection;
usually results in death or permanent disability. Patient selection guidelines are for
patients with relapsing-remitting disease whose other treatment (efficacy or intolerability)
has failed or who have an aggressive initial course; it should not be used in combination
with other disease-modifying therapies. On January 20, 2012, an FDA-issued drug safety
communication associated positive tests for John Cunningham virus (JCV) antibodies
as a risk factor for progressive multifocal leukoencephalopathy. Thus, patients with all
three of the following risk factors—presence of antiJCV antibodies, longer duration of
natalizumab treatment (especially beyond 2 years), and previous treatment with an immu-
nosuppressant medication (mitoxantrone, azathioprine, methotrexate, cyclophospha-
mide, mycophenolate mofetil)—are at 1.1% chance of developing progressive multifocal
leukoencephalopathy.
(c) Antibodies to natalizumab, associated with increased relapses and hypersensitivity reac-
tions, develop in 9%–12% of patients.
h. Teriflunomide (Aubagio)
i. Mechanism of action: Prevents activation of lymphocytes
ii. Indicated for relapsing forms of multiple sclerosis
iii. Pharmacokinetics: Long half-life (8–19 days); takes about 3 months to reach steady-state con-
centrations; takes an average of 8 months to eliminate drug (serum concentrations less than
0.02 mcg/mL) and may take up to 2 years
iv. Adverse effects
(a) Hepatotoxicity may occur; teriflunomide should not be used in patients with preexisting
liver disease or with alanine aminotransferase more than 2 times the upper limit of normal
(b) GI effects: Diarrhea, nausea
(c) Dermatologic effects: Alopecia, rash
(d) Infection: Neutropenia and lymphopenia may occur; tuberculosis infections reported
(negative tuberculosis skin test required at baseline); live virus vaccinations should not be
administered.
(e) Teratogenic: Pregnancy category X (based on animal studies); negative pregnancy test
at baseline; adequate contraception should be ensured; if pregnancy desired for men or
women, teriflunomide should be discontinued, accelerated elimination procedures should
be undertaken, and two serum concentrations less than 0.02 mcg/mL taken 14 days apart
should be confirmed.
v. Accelerated elimination procedures
(a) Cholestyramine 8 g every 8 hours for 11 days (if not tolerated, may use 4 g)
(b) Activated charcoal powder 50 g every 12 hours for 11 days
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-127
Neurology
3. Symptomatic therapies
a. Patients may have fatigue, spasticity, urinary incontinence, pain, depression, cognitive impair-
ment, fecal incontinence, constipation, pseudobulbar affect, and sexual dysfunction; treatment
should be with standard therapies for these symptoms.
b. Fatigue: Treatment may be nonpharmacologic (rest, assistive devices, cooling strategies, exercise,
stress management) or pharmacologic (amantadine, methylphenidate).
c. Spasticity: Therapies must be centrally acting.
i. First line: Baclofen, tizanidine
ii. Second line: Dantrolene, diazepam
iii. Third line: Intrathecal baclofen
iv. Focal spasticity: Botulinum toxin
d. Walking impairment: Dalfampridine (Ampyra)
i. Indicated to improve walking in patients with multiple sclerosis by improving walking speed
ii. Potassium channel blocker, prolongs action potentials in demyelinated neurons
iii. Dose: 10 mg orally twice daily; extended-release tablets
iv. Contraindicated in patients with a history of seizures or moderate or severe renal impairment
v. Adverse effects: Seizures, urinary tract infections, insomnia
e. Pseudobulbar affect: Dextromethorphan/quinidine
i. Affects 10% of patients
ii. Episodes of inappropriate laughing or crying
iii. Dextromethorphan prevents excitatory neurotransmitter release.
iv. Low-dose quinidine blocks first-pass metabolism of dextromethorphan, thus increasing dex-
tromethorphan serum concentrations.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-128
Neurology
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-129
Neurology
Patient Cases
Questions 26–28 pertain to the following case.
S.F. is a 33-year-old African American woman of Cuban descent living in the Miami area. This morning, her right
leg became progressively weaker over about 3 hours. She was previously healthy except for a broken radius when
she was 13 years old and a case of optic neuritis when she was 25 years old.
28. S.F. elects to start interferon beta-1b and wants to know whether she can prevent or minimize some of the
adverse effects. Which advice is best?
A. Always give the injection at the same time of day.
B. Lie down for 2 hours after the injection.
C. Rotate injection sites.
D. Use a heating pad on the injection sites.
29. B.B. is a 33-year-old woman with a recent diagnosis of multiple sclerosis. Her neurologist wants you to dis-
cuss with her potential medications to prevent exacerbations. During the discussion, you find that she and her
husband plan to have a child in the next few years and that she is terrified of needles. Which choice is best for
B.B.?
A. Glatiramer acetate.
B. Mitoxantrone.
C. Teriflunomide.
D. Dimethyl fumarate.
A. A broad range of diseases that result in damage to nerves that are outside the brain and spinal cord. Other
terms for peripheral neuropathy include peripheral neuritis, polyneuropathy, and polyneuritis.
1. More than 100 types; each is unique
2. Can be classified as acute or chronic. In addition, can be predominantly motor, mixed motor and sen-
sory, or predominantly sensory
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-130
Neurology
B. Epidemiology
1. 20 million people have some form of peripheral neuropathy in the United States.
2. Most common form is diabetic neuropathy. Diabetic peripheral neuropathy can occur before an official
diagnosis of diabetes and may be the presenting symptom of diabetes.
C. Clinical Course
1. Patients may initially present with altered sensation, pain, weakness, or autonomic symptoms.
Symptoms are typically present distally in the initial stages.
2. Symptoms may be bilateral or unilateral, symmetrical or asymmetrical.
3. Symptoms progress proximally. In advanced stages, distal wasting, weakness, absent deep tendon
reflexes, and glove and stocking sensory loss may occur.
D. Diagnosis
1. Complete medical history, medication history, and neurologic examination
2. Electromyelogram and nerve conduction studies
3. Laboratory tests to include serum chemistry, complete blood cell count, toxicology screen, vitamin B12
concentration, immune panel
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-131
Neurology
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-132
Neurology
Special Acknowledgment: ACCP gratefully acknowledges the contribution of the previous author, Dr. Melody
Ryan, and Dr. Timothy Welty to this chapter.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-133
Neurology
REFERENCES
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-134
Neurology
American Stroke Association. Stroke 2016;47:581- long-standing Parkinson disease. A short review of
641. Comprehensive, recent analysis of data to surgical treatments is also included.
support or refute exclusion criteria for tissue plas- 3. Miyasaki JM, Shannon K, Voon V, et al. Practice
minogen activator use in ischemic stroke. parameter: evaluation and treatment of depres-
3.
Goldstein LB, Bushnell CD, Adams RJ, et al. sion, psychosis, and dementia in Parkinson dis-
Guidelines for the primary prevention of stroke: ease (an evidence-based review). Report of the
a guideline for healthcare professionals from the Quality Standards Subcommittee of the American
American Heart Association/American Stroke Academy of Neurology. Neurology 2006;66:996-
Association. Stroke 2011;42:517-84. This is an 1002. Available at www.neurology.org/cgi/
extremely detailed discussion of the risk factors reprint/66/7/983.pdf. Accessed October 15, 2013.
for stroke and their influence on primary stroke Reviews available evidence on depression, psycho-
occurrence. sis, and dementia. Provides more in-depth reading
4.
Lansberg MG, O’Donnell MJ, Khatri P, et al. and summarizes most clinical trials on the subject.
Antithrombotic and thrombolytic therapy for 4. Olanow CW, Stern MB, Sethi K. The scientific
ischemic stroke: Antithrombotic Therapy and and clinical basis for the treatment of Parkinson
Prevention of Thrombosis, 9th ed. American disease (2009). Neurology 2009;72(suppl 4):S1-136.
College of Chest Physicians Evidence-Based An extensive treatise on pathophysiology and
Clinical Practice Guidelines. Chest 2012;141:e601S- treatment of Parkinson disease.
36S. Comprehensive review of evidence for sec- 5.
Pahwa R, Factor SA, Lyons KE, et al. Practice
ondary stroke prevention. parameter: treatment of Parkinson disease with
5. You JJ, Singer DE, Howard PA, et al. Antithrombotic motor fluctuations and dyskinesia (an evidence-
and thrombolytic therapy for atrial fibrilla- based review). Report of the Quality Standards
tion: Antithrombotic Therapy and Prevention of Subcommittee of the American Academy of
Thrombosis, 9th ed. American College of Chest Neurology. Neurology 2006;66:983-95. Available at
Physicians Evidence-Based Clinical Practice www.neurology.org/cgi/reprint/66/7/983. Accessed
Guidelines. Chest 2012;141:e531S-75S. Gold stan- October 15, 2013. Reviews available evidence on
dard for anticoagulation recommendations in atrial motor adverse effects and their treatment. Good for
fibrillation. more in-depth reading.
6. Zesiewicz TA, Sullivan KL, Amulf I, et al. Practice
Parkinson Disease parameter: treatment of nonmotor symptoms of
1. Horstink M, Tolosa E, Bonuccelli U, et al. Review Parkinson disease. Report of the Quality Standards
of the therapeutic management of Parkinson’s dis- Subcommittee of the American Academy of
ease. Report of a joint task force of the European Neurology. Neurology 2010;74:924-31. Provides
Federation of Neurological Societies and the detailed reading on treating symptoms other than
Movement Disorder Society—European Section. the cardinal signs of Parkinson disease.
Part I. Early (uncomplicated) Parkinson’s disease.
Eur J Neurol 2006;13:1170-85. Guidelines for treat- Headaches
ment of the patient who has recently received a 1. Francis GJ, Becker WJ, Pringsheim TM. Acute and
diagnosis of Parkinson disease. preventative pharmacologic treatment of cluster
2. Horstink M, Tolosa E, Bonuccelli U, et al. Review headache. Neurology 2010;75:463-73. Systematic
of the therapeutic management of Parkinson’s dis- review and meta-analysis of treatment trials for
ease. Report of a joint task force of the European cluster headache. Endorsed by the American
Federation of Neurological Societies and the Academy of Neurology.
Movement Disorder Society—European Section. 2.
Holland S, Silberstein SD, Freitag F, et al.
Part II. Late (complicated) Parkinson’s disease. Eur Evidence-based guideline update: NSAIDs and
J Neurol 2006;13:1186-202. Similar to the above other complementary treatments for episodic
reference but with an emphasis on the patient with migraine prevention in adults: report of the
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-135
Neurology
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-136
Neurology
1. Answer: A 300 mg/day to 600 mg/day would more than double the
Leukopenia (Answer A) is a common adverse effect serum concentration (Answers A, B, and C). A con-
of carbamazepine. Up to 10% of patients have a tran- centration of at least 20 mcg/mL (Answer D) would be
sient decrease in their white blood cell count; however, expected with this large of increase
the potential for serious hematologic abnormalities,
including agranulocytosis and aplastic anemia, exists. 6. Answer: D
Complete blood cell counts are recommended before ini- Ethosuximide (Answer D) is indicated for absence sei-
tiation and periodically during therapy. Carbamazepine zures. Phenytoin (Answer A), tiagabine (Answer B),
has not been associated with renal failure (Answer B), and carbamazepine (Answer C) are not indicated for
congestive heart failure (Answer C), or hypercalcemia absence seizures and may in some cases exacerbate this
(Answer D). type of seizure.
2. Answer: A 7. Answer: A
In general, dermatologic reactions to anticonvulsants Drowsiness (Answer A) is a dose-related adverse effect
occur after a delay of 2–8 weeks rather than immedi- of phenytoin. Acne (Answer B), gingival hyperplasia
ately after medication initiation (Answer A). Unless he (Answer C), and rash (Answer D) can also be adverse
had previously been exposed to carbamazepine, which effects, but they are not dose-related.
is unlikely since this is a new prescription, a rash will
not occur after a single first dose (Answer B). While 8. Answer: C
there is a constellation of adverse reactions to carba- Valproic acid and its derivatives are associated with
mazepine that include leukopenia, thrombocytopenia, alopecia (Answer C). Oligohidorsis (Answer A),
and hepatotoxicity, there is no evidence that hepatic renal stones (Answer B), and word-finding difficul-
failure results in rash with carbamazepine (Answer C). ties (Answer D) are adverse effects associated with
topiramate.
3. Answer: D
The rash that occurs with lamotrigine is often related to 9. Answer: D
the speed of titration (Answer D). Psychomotor slow- Carbamazepine forms an active epoxide intermedi-
ing (Answer A), renal stones (Answer B), and pares- ate (carbamazepine-10,11-epoxide), whereas oxcarba-
thesias (Answer C) are associated with topiramate and zepine does not (Answer D). Carbamazepine induces
zonisamide. more liver enzymes than oxcarbazepine, making
Answer A incorrect. However, hyponatremia is more
4. Answer: B closely associated with oxcarbazepine than with carba-
Lorazepam is the drug of choice for status epilepticus mazepine, making Answer C incorrect. Both drugs can
(Answer B). It is less lipophilic than diazepam (Answer cause allergic rashes, making Answer B incorrect.
A); therefore, it does not redistribute from the CNS as
quickly. A long-acting drug, such as phenytoin (Answer 10. Answer: C
C) and phenobarbital (Answer D) should be adminis- Since she is already pregnant and her seizures are
tered only after seizures are controlled or if repeated well-controlled, it is best to continue her current antie-
doses of a benzodiazepine do not stop seizures. They pileptic medication (Answer C). Immediate discontin-
should not be used in the initial treatment of status uation (Answer A) of an antiepileptic drug will likely
epilepticus. result in recurrence of seizures. Abrupt discontinuation
with the addition of folic acid (Answer B), still puts her
5. Answer: D at great risk for seizure recurrence. Changing her med-
Phenytoin shows nonlinear pharmacokinetics. A small ication to phenobarbital (Answer D) is not advisable,
increase in dose may result in a large increase in serum because phenobarbital may not control her seizures and
concentration. Therefore, without performing any it is associate with more birth defects than carbamaze-
calculations, we can surmise that an increase from pine or oxcarbazepine.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-137
Neurology
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-138
Neurology
old. Trihexyphenidyl (Answer A) would control his treatment. Ergotamine with caffeine (Answer B) has a
tremor but would not improve his difficulty walking, NNT higher than eletriptan, indicating it is less effec-
which probably represents bradykinesia. Entacapone tive. The NNT does not say anything about the occur-
(Answer B) is a COMT inhibitor; it should only be used rence of adverse effects (Answers C and D).
in conjunction with carbidopa/levodopa. Apomorphine
(Answer C) is for severe on-off symptoms. 26. Answer: D
Methylprednisolone (Answer D) is the only option
21. Answer: A used for treating acute exacerbations. Other options are
A β-blocker (Answer A) is a good choice for a patient high-dose oral prednisone or adrenocorticotropic hor-
with the coexisting condition of hypertension. Valproic mone. Interferon beta-1a (Answer A), glatiramer ace-
acid (Answer B) and amitriptyline (Answer C) could tate (Answer B), and mitoxantrone (Answer C) are all
both increase weight gain in a patient with morbid used as disease-modifying therapies and are not used in
obesity. Lithium (Answer D) is used for prophylaxis of acute exacerbations.
cluster headaches.
27. Answer: C
22. Answer: C The glatiramer acetate (Answer C) is an appropriate ini-
Amitriptyline (Answer C) is as effective as prophylaxis tial choices for disease-modifying therapy. Prednisone
for tension headaches. β-blockers (Answer A) and val- (Answer D) is not used as a disease-modifying agent.
proic acid (Answer B) are usually used for migraine Methotrexate (Answer A) is not used in the treatment
headache prophylaxis. Lithium (Answer D) is used for of multiple sclerosis. Amantadine (Answer B) is not a
prophylaxis of cluster headaches. disease-modifying treatment.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-139
Neurology
1. Answer: C 4. Answer: C
The therapeutic range for phenytoin is 10–20 mcg/ Patients who can be treated within 4½ hours of stroke
mL. The patient continues to have seizures, but has no symptom onset should be considered for tissue plas-
complaints of dose-related adverse effects. Phenytoin minogen activator. It has been 6 hours since the onset of
follows zero-order pharmacokinetics, resulting in the symptoms, making Answer A incorrect. He has already
need for caution in dose adjustments. With a concentra- been receiving aspirin 81 mg daily, but still had a stroke
tion of 7–12 mg/L, a dose adjustment of 50 mg/day is making Answer B incorrect. Recent studies indicate
appropriate (Answer C). Reducing the dose (Answer A) that a loading dose of clopidogrel followed by a com-
would potentially result in increased seizures. Keeping bination of aspirin and clopidogrel for 90 days (Answer
the phenytoin dose the same (Answer B) is inappropri- C) is more effective that either drug alone. Aspirin with
ate give the fact that he continues to have seizures. A dipyridamole (Answer D) has not been extensively
dose increase of 100 mg/day (Answer D) is too large, studied for preventing recurrent stroke during the
due to the zero-order pharmacokinetics of phenytoin. immediate post-stroke time frame.
2. Answer: B 5. Answer: D
Once the seizures of status epilepticus have been All stroke survivors need secondary stroke prevention
stopped, a second, long-acting drug should be initiated drugs. If he claims to be adherent to aspirin (Answer
to prevent seizure recurrence. Levetiracetam (Answer B) when his first stroke occurred, a different drug is
B) is well tolerated, has good efficacy as monotherapy, usually considered. Clopidogrel (Answer D) or dipyrid-
and has less risk of teratogenicity. Topiramate (Answer amole/aspirin would be an acceptable choice. Warfarin
A) and zonisamide (Answer C) are possibilities, but (Answer C) is indicated only in the case of atrial fibril-
they carry a greater risk of adverse effects and may be lation or other heart defects. Dipyridamole (Answer
associated with a higher risk of birth defects. Clobazam A) is ineffective unless combined with aspirin in an
(Answer D) is indicated only for Lennox-Gastaut syn- extended release dosage form.
drome, an unlikely diagnosis for this patient.
6. Answer: B
3. Answer: C Wearing off (Answer A) is the return of symptoms
Psychomotor slowing (e.g., difficulty concentrating, before the next dose. It has a definite pattern, whereas
difficulty thinking, word-finding difficulties, and a on-off (Answer B) is unpredictable. Dyskinesias
feeling of slowness of movement) is a very troublesome (Answer C) and dystonias (Answer D) are long-term
adverse effect for many patients initiated on topira- adverse effects of carbidopa/levodopa.
mate. The usual dosage titration for topiramate calls
for increasing the dose every week, but this patient 7. Answer: D
has been increasing the topiramate dose every other The first apomorphine dose must be given in a clinic
day. Because psychomotor slowing is related to the setting, making Answer A incorrect. The patient should
speed of titration, this makes slowing the titration rate not take apomorphine if he is allergic to metabisulfite,
(Answer C) the most probable answer. Partial seizures making Answer B incorrect. The dose should be re-
(Answer B) could present as confusion; however, they titrated if he has not taken apomorphine for 1 week,
are unlikely to be a continuous condition. Psychomotor making Answer C incorrect. Apomorphine causes
slowing can occur with supratherapeutic concentra- severe nausea and vomiting (Answer D).
tions (Answer D), but this is unlikely during an initial
titration schedule. Psychomotor slowing is not an aller-
gic reaction (Answer A).
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-140
Neurology
11. Answer: D
Fingolimod (Answer D) is the only given choice with
an FDA indication for the treatment of multiple scle-
rosis. In addition, it has the best clinical trial evidence
of efficacy. Methylprednisolone (Answer B) is used
for treating acute multiple sclerosis exacerbations.
Cyclophosphamide (Answer C) and azathioprine
(Answer A) have been studied in progressive forms of
multiple sclerosis, but their data are not as robust as
those for fingolimod.
12. Answer: B
Treatment of spasticity in multiple sclerosis requires
the use of a centrally acting agent. Of the choices given,
only diazepam (Answer A) and baclofen (Answer B)
are centrally acting. Because of the significant fatigue
and drowsiness that occurs with diazepam, baclofen is
usually a first-line therapy. Carisoprodol (Answer C)
and metaxalone (Answer D) are not centrally acting and
are not indicated for treatment of true spasticity.
ACCP Updates in Therapeutics® 2017: Pharmacotherapy Preparatory Review and Recertification Course
1-141